Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) were up 2.5% during trading on Friday . The stock traded as high as $8.64 and last traded at $8.64, with a volume of 64,702 shares. The stock had previously closed at $8.43.

Several analysts have recently commented on FOMX shares. Zacks Investment Research cut Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Guggenheim restated a “buy” rating and set a $10.00 target price on shares of Foamix Pharmaceuticals in a report on Tuesday, May 10th. Finally, TheStreet upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 2nd.

The stock’s market cap is $264.91 million. The stock’s 50-day moving average is $7.83 and its 200-day moving average is $6.77.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The company earned $1.50 million during the quarter, compared to analyst estimates of $1.10 million. On average, equities analysts forecast that Foamix Pharmaceuticals Ltd. will post ($0.92) EPS for the current year.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.